RBC Capital Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)

In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report), with a price target of $24.00. The company’s shares closed yesterday at $14.50.

According to TipRanks, Issi is an analyst with an average return of -22.8% and a 19.80% success rate. Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Lexeo Therapeutics, Inc. is a Strong Buy with an average price target of $21.33.

LXEO market cap is currently $386.4M and has a P/E ratio of -5.65.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lexeo Therapeutics, Inc. (LXEO) Company Description:

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.